De patienter, der modtog Vidaza, overlevede i gennemsnit i 24, 5 måneder sammenlignet med 15, 0 måneder for de patienter, der modtog konventionel behandling.
Patients receiving Vidaza survived for an average of 24.5 months, compared with 15.0 months in patients receiving conventional care.